Clinical Trials Browser

Phase 3 × Interventional × cemiplimab × Clear all

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

789 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Suspended

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06246916 2026-05-06

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Phase 3 Recruiting

Melanoma

NCT05352672 2026-04-22

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Neoplasm Metastasis

NCT06585410 2026-04-22

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

Skin Neoplasms

NCT05317858 2026-04-16

LIMITLESS

Phase 3 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06931717 2026-04-14

ARCH

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 1 FDA

Cutaneous Squamous Cell Carcinoma

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT03257267 2025-04-08

Study of Cemiplimab in Adults With Cervical Cancer

Phase 3 Completed

608 enrolled 18 charts

Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03515629 2022-11-16

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Phase 3 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung